Diagnosis, Clinical Manifestations and Management of Rare Bleeding Disorders in Iran Publisher Pubmed



Dorgalaleh A¹ ; Alavi SER² ; Tabibian S¹ ; Soori S¹ ; Moradi E³ ; Bamedi T⁴ ; Asadi M⁵ ; Jalalvand M⁶ ; Shamsizadeh M⁷ Show Affiliations
Source: Hematology Published:2017

Abstract

Background: Rare bleeding disorders (RBDs) are heterogeneous disorders, mostly inherited in an autosomal recessive pattern. Iran is a Mideast country with a high rate of consanguinity that has a high rate of RBDs. Objective: In this study, we present prevalence and clinical presentation as well as management and genetic defects of Iranian patients with RBDs. Methods: For this study, all relevant publications were searched in Medlin until 2015. Results and discussion: Iran has the highest global incidence of factor XIII deficiency. Factor VII deficiency also is common in Iran, while factor II deficiency, with a prevalence of 1 per ∼3 million, is the rarest form of RBDs. Factor activity is available for all RBDs except for factor XIII deficiency, in which clot solubility remains as a diagnostic test. Molecular analysis of Iranian patients with RBDs revealed a few recurrent, common mutations only in patients with factor XIII deficiency, and considerable novel mutations in other RBDs. Clinical manifestations of these patients are variable and patients with factor XIII, factor X and factor VII more commonly presented severe life-threatening bleeding, while patients with combined factor V and factor VIII presented a milder phenotype. Plasma-derived products are the most common therapeutic choice in Iran, used prophylactically or on-demand for the management of these patients. Conclusion: Since Iran has a high rate of RBDs with life-threatening bleeding, molecular studies can be used for carrier detection and, therefore, prevention of the further expansion of these disorders and their fatal consequence. © 2016 Informa UK Limited, trading as Taylor & Francis Group.